Eli Lilly's bid for approval for an experimental weight-loss pill got a boost on Wednesday with new clinical trial data, and ...

Eli Lilly's orforglipron beat NVO's Rybelsus in a 52-week diabetes study, showing stronger A1C and weight loss benefits.

Makers of GLP-1 drugs, including Novo Nordisk and Eli Lilly, are close to releasing pills taken daily to help shed pounds as an alternative to weekly injections.

Ousted CDC director Susan Monarez says Kennedy planned to change pediatric vaccine schedule; Eli Lilly’s obesity pill beats Novo’s Rybelsus in latest study; Novo views semaglutide trial in Alzheimer’s ...

Gen Z borrowers took the biggest hit of any age group this year, helping pull overall credit scores lower in the worst year ...

In today’s Pharmaceutical Executive Daily, we cover Lilly’s orforglipron as a prime candidate for FDA fast-track approval, ...

Eli Lilly's bid for approval for an experimental weight-loss pill got a boost on Wednesday with new clinical trial data, but company executives said it was too soon to assume the drug will be part of ...

In a trial comparing two oral GLP-1s, orforglipron was superior to semaglutide for glycemic control and weight loss in ...

The data in non-diabetic subjects with obesity (a body mass index of 30 or more) reveal that patients on a 6 mg daily dose of ...

In a late-stage trial, an investigational GLP-1 pill from Eli Lilly helped diabetes patients lower their blood sugar and ...

Patients on Eli Lilly & Co.’s experimental diabetes pill lost more weight and had better blood sugar control than those on an ...

The 7- and 14-mg semaglutide doses included in Lilly’s trial match those of Novo’s Rybelsus, an oral version of the GLP-1 semaglutide that is approved as a first-line treatment option in type 2 ...